NobleOak Life Valuation
Is NOL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of NOL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: NOL (A$1.67) is trading above our estimate of fair value (A$1.44)
Significantly Below Fair Value: NOL is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NOL?
Key metric: As NOL is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is NOL's PE Ratio? | |
|---|---|
| PE Ratio | 15.3x |
| Earnings | AU$9.28m |
| Market Cap | AU$142.10m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.2x |
| Enterprise Value/EBITDA | 6x |
| PEG Ratio | 0.6x |
Price to Earnings Ratio vs Peers
How does NOL's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 73.5x | ||
CVW ClearView Wealth | 30.3x | 40.8% | AU$211.8m |
GDG Generation Development Group | 194.3x | 42.3% | AU$1.1b |
NHF nib holdings | 14.8x | 6.3% | AU$2.8b |
ENA Ensurance | 54.6x | n/a | AU$24.3m |
NOL NobleOak Life | 15.3x | 23.9% | AU$142.1m |
Price-To-Earnings vs Peers: NOL is good value based on its Price-To-Earnings Ratio (15.3x) compared to the peer average (79.8x).
Price to Earnings Ratio vs Industry
How does NOL's PE Ratio compare vs other companies in the Global Insurance Industry?
| 15 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 15 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: NOL is expensive based on its Price-To-Earnings Ratio (15.3x) compared to the Global Insurance industry average (11.3x).
Price to Earnings Ratio vs Fair Ratio
What is NOL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 15.3x |
| Fair PE Ratio | 22.5x |
Price-To-Earnings vs Fair Ratio: NOL is good value based on its Price-To-Earnings Ratio (15.3x) compared to the estimated Fair Price-To-Earnings Ratio (22.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | AU$1.67 | AU$2.98 +78.7% | 4.2% | AU$3.10 | AU$2.85 | n/a | 2 |
| Nov ’25 | AU$1.60 | AU$2.98 +85.9% | 4.2% | AU$3.10 | AU$2.85 | n/a | 2 |
| Oct ’25 | AU$1.64 | AU$2.98 +81.4% | 4.2% | AU$3.10 | AU$2.85 | n/a | 2 |
| Sep ’25 | AU$1.58 | AU$2.93 +85.7% | 2.6% | AU$3.00 | AU$2.85 | n/a | 2 |
| Aug ’25 | AU$1.45 | AU$2.83 +95.5% | 0.9% | AU$2.85 | AU$2.80 | n/a | 2 |
| Jul ’25 | AU$1.44 | AU$2.83 +96.9% | 0.9% | AU$2.85 | AU$2.80 | n/a | 2 |
| Jun ’25 | AU$1.58 | AU$2.83 +78.8% | 0.9% | AU$2.85 | AU$2.80 | n/a | 2 |
| May ’25 | AU$1.62 | AU$2.83 +74.9% | 0.9% | AU$2.85 | AU$2.80 | n/a | 2 |
| Apr ’25 | AU$1.62 | AU$2.83 +74.4% | 0.9% | AU$2.85 | AU$2.80 | n/a | 2 |
| Mar ’25 | AU$1.52 | AU$2.83 +85.9% | 0.9% | AU$2.85 | AU$2.80 | n/a | 2 |
| Feb ’25 | AU$1.56 | AU$2.73 +74.7% | 4.6% | AU$2.85 | AU$2.60 | n/a | 2 |
| Jan ’25 | AU$1.69 | AU$2.73 +61.2% | 4.6% | AU$2.85 | AU$2.60 | n/a | 2 |
| Dec ’24 | AU$1.75 | AU$2.73 +55.7% | 4.6% | AU$2.85 | AU$2.60 | n/a | 2 |
| Nov ’24 | AU$1.75 | AU$2.73 +55.7% | 4.6% | AU$2.85 | AU$2.60 | AU$1.60 | 2 |
| Oct ’24 | AU$1.70 | AU$2.73 +60.3% | 4.6% | AU$2.85 | AU$2.60 | AU$1.64 | 2 |
| Sep ’24 | AU$1.81 | AU$2.73 +51.0% | 4.6% | AU$2.85 | AU$2.60 | AU$1.58 | 2 |
| Aug ’24 | AU$1.67 | AU$2.78 +66.7% | 2.7% | AU$2.85 | AU$2.70 | AU$1.45 | 2 |
| Jul ’24 | AU$1.80 | AU$2.78 +54.6% | 2.7% | AU$2.85 | AU$2.70 | AU$1.44 | 2 |
| Jun ’24 | AU$1.65 | AU$2.78 +68.7% | 2.7% | AU$2.85 | AU$2.70 | AU$1.58 | 2 |
| May ’24 | AU$1.74 | AU$2.78 +59.9% | 2.7% | AU$2.85 | AU$2.70 | AU$1.62 | 2 |
| Apr ’24 | n/a | AU$2.78 0% | 2.7% | AU$2.85 | AU$2.70 | AU$1.62 | 2 |
| Mar ’24 | AU$1.73 | AU$2.38 +37.5% | 23.6% | AU$2.85 | AU$1.59 | AU$1.52 | 3 |
| Feb ’24 | AU$1.78 | AU$2.38 +33.7% | 23.6% | AU$2.85 | AU$1.59 | AU$1.56 | 3 |
| Jan ’24 | AU$1.75 | AU$2.38 +36.4% | 23.6% | AU$2.85 | AU$1.59 | AU$1.69 | 3 |
| Dec ’23 | AU$1.77 | AU$2.38 +34.8% | 23.6% | AU$2.85 | AU$1.59 | AU$1.75 | 3 |
| Nov ’23 | AU$1.65 | AU$2.36 +43.1% | 23.2% | AU$2.80 | AU$1.59 | AU$1.75 | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Medibank Private
AU$10.4b
Provides private health insurance and health services in Australia.
MPL
AU$3.78
7D
1.1%
1Y
9.2%
Suncorp Group
AU$13.4b
Provides insurance and banking products and services to retail, corporate, and commercial customers in Australia and New Zealand.
SUNPF
AU$100.70
7D
0%
1Y
-1.3%
Tower
NZ$508.5m
Provides general insurance products in New Zealand and the Pacific Islands.
TWR
NZ$1.22
7D
4.3%
1Y
117.0%